Arecor is developing an ultra-rapid acting insulin that more closely matches a healthy body’s physiological response to blood glucose, which will be a major advancement for diabetes care. Even faster acting insulins should lead to better postprandial glycaemic control, reduction in variability, improved HbA1c and allow greater flexibility in the timing of insulin injections.